Bright Minds Biosciences Inc. - common stock — 재무제표 (NASDAQ:DRUG)

Financials

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use. It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens. The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York.

DRUG

Financials

Bright Minds Biosciences Inc. - common stock

뉴스

브라이트 마인즈, 목표 주가 145달러로 상향 조정

Bright Minds stock price target raised to $145 by H.C. Wainwright on trial data

Bright Minds, 1억 7,505만 달러 규모 공모 마감

Bright Minds Biosciences closes $175 million public offering

Bright Minds Biosciences, 주당 $90에 공모가 결정

Bright Minds Biosciences prices public offering at $90 per share

Bright Minds, 1억 7,505만 달러 규모 공모가 결정

Bright Minds Biosciences prices $175 million public offering

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Bright Minds Biosciences 목표 주가, BTIG, 194,500원으로 상향

Bright Minds Biosciences stock price target raised to $147 by BTIG

Crude Oil Down 2%; ISM Services PMI Surges In December - Curis (NASDAQ:CRIS), Bright Minds Biosciences (NASDAQ:DRUG)